Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 7/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21052221 | 0.89 | LMNA (0.42) | LMNAMAPK1MAPTMEN1KMT2A | |
| SCHEMBL18037721 | 0.79 | MAPT (0.42) | LMNAPOLBMAPK1MAPTTP53 | |
| SCHEMBL12679101 | 0.79 | MAPT (0.42) | LMNAPOLBMAPK1MAPTTP53 | |
| SCHEMBL17231868 | 0.79 | MAPT (0.42) | LMNAPOLBMAPK1MAPTTP53 | |
| SCHEMBL21052173 | 0.78 | MAPT (0.41) | LMNAPOLBMAPTGAAMEN1 | |
| SCHEMBL16692028 | 0.78 | MAPT (0.53) | LMNAPOLBMAPK1MAPTTP53 | |
| SCHEMBL17236156 | 0.77 | MAPT (0.50) | LMNAPOLBMAPK1MAPTTP53 | |
| SCHEMBL16687019 | 0.77 | MAPT (0.50) | LMNAPOLBMAPK1MAPTTP53 | |
| SCHEMBL12679100 | 0.77 | MAPT (0.50) | LMNAPOLBMAPK1MAPTTP53 | |
| SCHEMBL29527619 | 0.77 | MAPT (0.30) | MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9902691-B2 | Intermediates and methods for synthesizing calicheamicin derivatives | PFIZER INC. (US) | 2018-02-27 | — | — | US | disclosed |
| US-20160251389-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | PFIZER INC. (US) | 2016-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160251389-A1 | INTERMEDIATES AND METHODS FOR SYNTHESIZING CALICHEAMICIN DERIVATIVES | CALR, CALD1, CYCS | LMNA 1521/4885POLB 1877/4885MAPK1 2572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.